

Hypercholesterolemia Enrollment Form



PATIENT INFORMATION

Patient Name: _____ Phone: (____) - ____ - _____
 Date of Birth: ____ / ____ / ____ Male Female Email: _____
 SSN: ____ - ____ - ____ Preferred method of contact: Phone Email
 Address: _____ Height: ____ in Weight: ____ lb Date: ____ / ____ / ____
 City: _____ State: _____ Zip: _____ Allergies: _____ Medications: _____ (Please attach additional pages if necessary)

PRESCRIPTION BENEFITS INFORMATION (Please attach front and back of insurance card)

Plan name: _____ ID#: _____ Group #: _____ RxBIN: _____ RxPCN: _____

PRESCRIBER INFORMATION

Prescriber Name: _____ Phone: (____) - ____ - _____ Fax: (____) - ____ - _____
 Address: _____ License #: _____
 City: _____ State: _____ Zip: _____ NPI #: _____
 Contact: _____ Clinic/Hospital Affiliation: _____ Medicaid Provider #: _____

LIPRX-20-01

CLINICAL CONSIDERATIONS

Diagnosis:
 E78.01 Familial Hypercholesterolemia
 Type: HeFH (Heterozygous) HoFH (Homozygous)
 E78.0 Pure Hypercholesterolemia
 E78.2 Mixed Hyperlipidemia
 E78.4 Other Hyperlipidemia
 E78.5 Unspecified Hyperlipidemia

Please list previously tried/failed therapies & dates:
Should be on maximally tolerated statin therapy

Immunization History
 Influenza
 Date: ____ / ____ / ____

Current LDL-C Value: _____
 Date of test: ____ / ____ / ____



Medication	Dose/Strength	Directions	Quantity	Refills
<input type="checkbox"/> Praluent® (alirocumab)	<input type="checkbox"/> 75 mg/mL prefilled pen <input type="checkbox"/> 150 mg/mL prefilled pen	<input type="checkbox"/> Inject 75 mg subcutaneously every 2 weeks <input type="checkbox"/> Inject 150 mg subcutaneously every 2 weeks <input type="checkbox"/> Inject 300 mg (two 150 mg injections) subcutaneously every 4 weeks		
<input type="checkbox"/> Repatha® (evolocumab)	<input type="checkbox"/> 140 mg/mL prefilled syringe <input type="checkbox"/> 140 mg/mL SureClick® autoinjector	<input type="checkbox"/> Inject 140 mg subcutaneously every 2 weeks <input type="checkbox"/> Inject 420 mg subcutaneously once monthly (three 140 mg injections consecutively within 30 minutes)		
	<input type="checkbox"/> 420 mg/3.5 mL single-use Pushtronex™ system	<input type="checkbox"/> Inject 420 mg subcutaneously once monthly (over 9 minutes by using the on-body infusor)		

Injection Training

Injection training provided by Prescriber's Office Specialty Pharmacy Other: _____

By signing below, I authorize the pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization process. I also certify that the above therapy is medically necessary and that the information above is accurate to the best of my knowledge.

Prescriber's Signature: _____ MD DO PA CRNP **Date:** ____ / ____ / ____

NO STAMPS

In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary" on the prescription.

SHIPPING INFORMATION

Ship to: Patient Physician/Clinic Date Shipment Needed By: ____ / ____ / ____

